Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker SGMOQ · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fib… NCT06980948 · Chronic Neuropathic Pain ST-503, Sham (No Treatment) | SGMOQ Sangamo Therapeutics | Phase 1/2 | Suspended was recruiting | 27 | Jul 2027 | Registry ↗ |
| Oct 27, 2026 | Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With F… NCT04046224 · Fabry Disease ST-920 | SGMOQ Sangamo Therapeutics | Phase 1/2 | Completed | 36 | Apr 10, 2025 | Registry ↗ |
| Aug 20, 2026 | Long-Term Follow-up of Subjects Who Were Treated With ST-920 NCT05039866 · Fabry Disease, Fabry Disease, Cardiac Variant ST-920 | SGMOQ Sangamo Therapeutics | — | Active, not recruiting | 32 | Mar 2029 | Registry ↗ |
| Aug 13, 2026 | Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX NCT04628871 · Hemophilia B, Mucopolysaccharidosis I SB-318, SB-913 | SGMOQ Sangamo Therapeutics | — | Terminated | 13 | Jun 17, 2026 | Registry ↗ |
| Jul 2, 2026 | Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal T… NCT04817774 · Kidney Transplant Rejection, End Stage Renal Disease TX200-TR101 | SGMOQ Sangamo Therapeutics | Phase 1/2 | Completed | 26 | Jul 11, 2024 | Registry ↗ |
| Dec 4, 2025 | Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term) NCT05987527 · Kidney Transplant Rejection, End Stage Renal Disease Blood sample | SGMOQ Sangamo Therapeutics | — | Active, not recruiting | 11 | Jun 11, 2039 | Registry ↗ |
| Nov 12, 2025 | Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BI… NCT05145062 · Blood and Lymphatic Diseases BIVV003, ST-400 | SGMOQ Sangamo Therapeutics | — | Active, not recruiting | 8 | Jul 14, 2038 | Registry ↗ |
| Sep 12, 2025 | A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic St… NCT03653247 · Sickle Cell Disease Plerixafor, Busulfan | SGMOQ Sangamo Therapeutics | Phase 1/2 | Completed | 7 | Jul 17, 2025 | Registry ↗ |
| Jul 19, 2024 | Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With… NCT02695160 · Hemophilia B SB-FIX | SGMOQ Sangamo Therapeutics | Phase 1 | Terminated | 1 | Apr 19, 2021 | Registry ↗ |
| Jan 26, 2024 | Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T NCT04201782 · HIV-1-infection There are no disallowed treatments | SGMOQ Sangamo Therapeutics | — | Terminated | 38 | Jul 17, 2023 | Registry ↗ |
| Dec 14, 2023 | A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dep… NCT03432364 · Transfusion Dependent Beta-thalassemia ST-400 Investigational product | SGMOQ Sangamo Therapeutics | Phase 1/2 | Completed | 5 | Nov 17, 2022 | Registry ↗ |
| Jan 26, 2023 | Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subj… NCT02702115 · MPS I SB-318 | SGMOQ Sangamo Therapeutics | Phase 1/2 | Terminated | 3 | Nov 3, 2021 | Registry ↗ |
| Nov 10, 2022 | Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Pa… NCT00400634 · Idiopathic Parkinson's Disease CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturi… | SGMOQ Sangamo Therapeutics | Phase 2 | Completed | 58 | Nov 2008 | Registry ↗ |
| Nov 10, 2022 | Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease NCT00252850 · Parkinson's Disease CERE-120: AAV2-NTN | SGMOQ Sangamo Therapeutics | Phase 1 | Completed | 12 | Mar 2007 | Registry ↗ |
| Nov 10, 2022 | CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease NCT00087789 · Alzheimer's Disease CERE-110: Adeno-Associated Virus Delivery of NGF | SGMOQ Sangamo Therapeutics | Phase 1 | Completed | 10 | May 2010 | Registry ↗ |
| Oct 25, 2022 | Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subj… NCT03041324 · Mucopolysaccharidosis II, MPS II SB-913 | SGMOQ Sangamo Therapeutics | Phase 1/2 | Terminated | 9 | May 7, 2021 | Registry ↗ |
| May 23, 2022 | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy NCT01079325 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 SB-509, Saline | SGMOQ Sangamo Therapeutics | Phase 2 | Completed | 170 | May 2015 | Registry ↗ |
| May 24, 2021 | Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T NCT01543152 · HIV SB-728-T, SB-728-T | SGMOQ Sangamo Therapeutics | Phase 1/2 | Completed | 26 | Jul 7, 2017 | Registry ↗ |
| Mar 19, 2021 | Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART NCT02225665 · Human Immunodeficiency Virus (HIV) SB-728mR-T, SB-728mR-T | SGMOQ Sangamo Therapeutics | Phase 1/2 | Completed | 8 | Jun 2018 | Registry ↗ |
| Dec 21, 2020 | Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Dise… NCT00876863 · Alzheimer's Disease CERE-110: Adeno-Associated Virus injection Surgery, Placebo… | SGMOQ Sangamo Therapeutics | Phase 2 | Completed | 49 | Aug 13, 2015 | Registry ↗ |
| Apr 16, 2020 | Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease NCT00985517 · Idiopathic Parkinson's Disease CERE-120: Adeno-Associated Virus Delivery of Neurturin, Sha… | SGMOQ Sangamo Therapeutics | Phase 1/2 | Completed | 57 | Nov 9, 2014 | Registry ↗ |
| Sep 20, 2019 | Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-I… NCT01252641 · HIV, HIV Infection SB-728-T | SGMOQ Sangamo Therapeutics | Phase 1/2 | Completed | 21 | Dec 2014 | Registry ↗ |
| Mar 13, 2015 | Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc F… NCT01044654 · HIV Infection, HIV Infections SB-728-T | SGMOQ Sangamo Therapeutics | Phase 1 | Completed | 19 | Dec 2014 | Registry ↗ |
23 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:08 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances